Open AccessTiming of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies
Author(s) -
Catherine Handy Marshall,
Yongmei Chen,
HuaiChing Kuo,
Jennifer Cullen,
Jiji Jiang,
Inger L. Rosner,
Mark C. Markowski,
David G. McLeod,
Bruce J. Trock,
Mario A. Eisenberger
Publication year - 2021
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1097/ju.0000000000001797
Subject(s) - medicine , prostate cancer , androgen deprivation therapy , metastasis , biochemical recurrence , prostatectomy , oncology , context (archaeology) , population , cancer , prostate specific antigen , paleontology , biology , environmental health
There were 3 recent U.S. Food and Drug Administration approvals for drugs to be used in nonmetastatic castration resistant prostate cancer, a state that arises from the unproven start of continuous androgen deprivation therapy (ADT) for biochemical recurrent prostate cancer (BCR), before metastatic disease is evident. This report examines the outcome of men with BCR who defer ADT until time of metastasis.